Portside Wealth Group LLC Has $7.05 Million Position in Eli Lilly and Company $LLY

Portside Wealth Group LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,045 shares of the company’s stock after selling 353 shares during the quarter. Eli Lilly and Company makes up approximately 1.0% of Portside Wealth Group LLC’s holdings, making the stock its 17th largest holding. Portside Wealth Group LLC’s holdings in Eli Lilly and Company were worth $7,051,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Braun Bostich & Associates Inc. boosted its holdings in Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after acquiring an additional 13 shares during the last quarter. Rise Advisors LLC lifted its position in Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares during the period. Occidental Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors boosted its stake in shares of Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock valued at $307,000 after purchasing an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. grew its position in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after buying an additional 13 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,023.32 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,033.62. The firm has a fifty day moving average of $832.59 and a 200-day moving average of $780.91. The firm has a market capitalization of $967.43 billion, a price-to-earnings ratio of 66.88, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the company posted $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LLY. Daiwa Capital Markets increased their price objective on shares of Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Scotiabank assumed coverage on Eli Lilly and Company in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,015.11.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.